Jounce Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kimberlee Cobleigh Drapkin CPA
- Full Time Employees
- 141
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 780 Memorial Drive Cambridge MA United States of America 02139
- IPO Date
- Jan 26, 2017
- CIK
- 0001640455
- Website
- jouncetx.com
- Similar Companies
- Business
- Jounce Therapeutics, Inc., a clinical-stage immunotherapy company focused on developing novel cancer therapies, advances monoclonal antibodies targeting immune checkpoints and tumor-associated macrophages, including vopratelimab (JTX-2011), a Phase II ICOS agonist for solid tumors; JTX-8064, a LILRB2 antagonist in Phase I INNATE trials as monotherapy and combined with pimivalimab, Jounce's anti-PD-1 antibody; pimivalimab for combination regimens; and preclinical candidates JTX-1484 and JTX-2134 designed to reduce myeloid suppression and activate T and NK cells. Founded in 2012 and headquartered in Cambridge, Massachusetts, the company primarily serves oncology markets through biomarker-driven approaches for advanced solid tumors such as non-small cell lung cancer and platinum-resistant ovarian cancer. In May 2023, Jounce became a subsidiary of Concentra Biosciences, LLC following a $1.85 per share cash acquisition plus contingent value rights tied to program dispositions, accompanied by an 84% workforce reduction and termination of a prior Redx Pharma merger; its website now redirects to Concentra, which continues integrating Jounce's pipeline amid ongoing 2025 buyout activities.
Marketing Architects Partners with Jounce Media for Greater Transparency in CTV Buying
Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
Penny Stocks To Buy Now: 7 To Watch Before Next Week
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
5 Top Penny Stocks To Buy In March According To Insiders
Navigating Volatile Penny Stocks: Essential Tips for Investors
Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics
Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?
Maximizing Returns With Penny Stocks: Day Trading
Why Is Jounce Therapeutics (JNCE) Stock Up 14% Today?
Jounce: Gilead's GS-1811 Buyout Allows A Further Bounce
How to Read Penny Stocks News and Use it to Profit
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
Gilead buys out rights to cancer therapy from Jounce for $67 mln
Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress
Jounce Therapeutics to Participate in the Upcoming Investor Conferences
Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down